Long-Acting Drugs Market to Reach US$ 13.3 Billion by 2033 Expands Amid Advances in Sustained Drug Delivery and Chronic Disease Management - Persistence Market Research
LONDON, June 30, 2026 /PRNewswire/ -- The global long-acting drugs market is growing steadily, expected to be valued at around US$ 7.2 billion in 2026 and projected to reach US$ 13.3 billion by 2033, with a CAGR of 8.9% in the coming years. This expansion comes from the increasing prevalence of chronic diseases, rising demand for patient-friendly therapies, and rapid innovation in sustained-release drug delivery systems. Long-acting formulations are increasingly used in oncology, diabetes, HIV, psychiatric disorders, and cardiovascular diseases, where consistent therapeutic levels are critical for long-term management.
Rising Burden of Chronic Diseases Fuels Demand for Long-Acting Therapies
The worldwide increase in chronic diseases is significantly boosting demand for long-acting drugs. Conditions such as cancer, diabetes, schizophrenia, HIV, and cardiovascular disorders require prolonged treatment regimens, where patient adherence often becomes a major challenge. Long-acting formulations address this issue by reducing dosing frequency and maintaining stable drug concentrations over weeks or months.
For instance, the World Health Organization reported nearly 20 million new cancer cases globally in 2022, while diabetes continues to affect more than 500 million people worldwide. This growing patient population is encouraging healthcare providers to adopt therapies that improve convenience and reduce relapse risks.
Long-acting injectables and polymer-based depots are increasingly used in psychiatric care, where treatment interruptions can lead to hospitalization. Similarly, HIV prevention therapies such as injectable cabotegravir have transformed adherence patterns by replacing daily oral regimens with bi-monthly dosing schedules.
Pharmaceutical companies are responding with advanced formulations that enhance bioavailability, extend therapeutic action, and minimize side effects. In 2025, investments in long-acting oncology and CNS therapies accelerated as healthcare systems prioritized improved patient outcomes and lower treatment costs.
Get a Free Sample: https://www.persistencemarketresearch.com/samples/34040
Key Highlights
Technological Advancements in Drug Delivery Systems Accelerate Innovation
Innovation in drug delivery technology is another major driver of the long-acting drugs market. Pharmaceutical companies are developing advanced systems such as microspheres, liposomes, biodegradable implants, and polymer depots to deliver controlled and sustained drug release.
Microsphere-based systems remain the dominant technology because they provide precise release profiles and improve drug stability. These formulations are widely used in oncology, hormonal therapies, and central nervous system disorders due to their ability to maintain therapeutic effectiveness for extended periods.
The rise of oral long-acting biologics also represents a transformative opportunity. Technologies using permeation enhancers and protective coatings are enabling peptide-based therapies to survive gastric degradation and maintain bioavailability. Products such as oral semaglutide and next-generation GLP-1 therapies demonstrate how sustained-release technologies are expanding beyond injectables.
Manufacturers are also investing in sensor-enabled delivery systems and smart packaging solutions that improve dose tracking and patient monitoring. These innovations support adherence while helping healthcare providers optimize treatment plans through real-time data collection.
Key Highlight: Eli Lilly Advances Oral GLP-1 Innovation in 2025
This development signals a broader transition toward patient-focused chronic disease therapies that prioritize ease of administration and long-term treatment adherence. The progress of oral GLP-1 medicines is expected to intensify competition within diabetes and obesity management markets, encouraging further investments in next-generation oral metabolic therapies.
Request a Customization: https://www.persistencemarketresearch.com/request-customization/34040
Segmentation Insights: Microsphere-Based Systems Lead Delivery Technology Segment with Superior Sustained-Release Performance
Microsphere-Based Systems dominate the delivery technology segment of the long-acting drugs market due to their ability to provide controlled and sustained drug release, improving therapeutic effectiveness and patient compliance. These biodegradable polymer particles gradually release active ingredients over weeks or months, significantly reducing dosing frequency in chronic disease treatments. The technology is widely used across oncology, hormonal therapies, CNS disorders, and infectious disease management because of its versatility and compatibility with injectable formulations. Microspheres also improve drug stability, bioavailability, and targeted delivery while minimizing side effects. Strong regulatory familiarity, expanding clinical adoption, and continuous advancements in biodegradable polymer technologies further strengthen their leadership position in the global long-acting drugs market.
Regional Insights: North America Leads Long-Acting Drugs Market While Asia Pacific Emerges as Fastest-Growing Regional Hub
North America holds the largest share of the long-acting drugs market, accounting for about 41.2% of global value, supported by strong pharmaceutical R&D activity, advanced healthcare infrastructure, and favorable regulatory approvals. The U.S. dominates regional demand due to increasing adoption of long-acting injectables in oncology, diabetes, schizophrenia, and HIV therapies. FDA approvals for sustained-release formulations and strong reimbursement policies continue to strengthen market expansion.
Asia Pacific is the fastest-growing region. China and India are leading regional growth due to rising chronic disease prevalence, improving healthcare access, and expanding pharmaceutical manufacturing capabilities. Government healthcare initiatives and growing investments in drug delivery innovation are encouraging adoption of long-acting therapies across large patient populations.
Europe follows with strong growth supported by aging populations, increasing clinical trial activity, and investments in advanced drug delivery technologies. Regulatory support from the European Medicines Agency and funding initiatives focused on innovative therapeutics continue to strengthen the region's position.
Key Players and Business Strategies
Leading players include Eli Lilly and Company, ViiV Healthcare, Johnson & Johnson, Novartis AG, and AstraZeneca plc.
Strategies across the industry emphasize advanced delivery technologies, expansion of chronic disease portfolios, patient-centric formulations, and partnerships supporting innovation in sustained-release therapeutics.
Buy Now: https://www.persistencemarketresearch.com/checkout/34040
Market Segmentation
By Delivery Technology
By Route of Administration
By Therapeutic Area
By Material Used
By Distribution Channel
By Region
Get More Insights — Related Healthcare Market Reports:
Sterile Injectable Drugs Market by Product Type (Large, Small Molecule), Drug Class (Monoclonal Antibodies, Cytokines, Insulin), Administration Route (Intradermal, Intramuscular), Dosage Form, and Regional Analysis for 2025 – 2032
U.S. Antipsychotic Drugs Market by Disease (Schizophrenia, Bipolar Disorder, Others), Therapeutic Class (First Generation, Second Generation, Third Generation), Distribution Channel (Hospital Pharmacies, Others), and Zone Analysis 2026 – 2033
Medical Marijuana Market by Product Type (Flowers, Edibles, Concentrates, Others), Application (Chronic Pain, Cancer, Mental Disorders, Others), End-user (Research & Development, Pharmaceutical), and Regional Analysis for 2026 – 2033
Injectable Drug Delivery Market by Device Type (Conventional Injection Devices, Prefilled Syringes, Auto-Injectors, Others), Route of Administration (Intravenous, Intramuscular, Subcutaneous), End-user (Hospitals & Clinics, Home Care Settings, Others), and Regional Analysis for 2026 – 2033
Metered Dose Inhalers Market by Inhaler Type (Standard Metered Dose Inhalers, Others), Disease Type (Asthma, COPD, Others), Medication Type (Reliever Inhalers, Preventive Inhalers, Combination Therapy Inhalers), and Regional Analysis for 2026 – 2033
Diabetic Nephropathy Market by Drug Class (ACE Inhibitors, Angiotensin Receptor Blockers, SGLT2 Inhibitors, Others), Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Others), and Regional Analysis for 2026 – 2033
Low and Middle Income Countries Opioid Substitution Therapy Market by Drug Class (Opioid Antagonists, Opioid Agonists and Partial Agonists), Indication (Pain Management, Opioid Withdrawal/Opioid Use Disorder (OUD), Others), and Regional Analysis for 2026 – 2033
Giant Cell Arteritis Treatment Market by Treatment Type (Corticosteroid Therapy, Immunosuppressive Agents, Anticoagulants, and Monoclonal Antibodies), Route of Administration (Oral, Intravenous, and Subcutaneous), and Regional Analysis for 2026 – 2033
Ciprofloxacin Market by Dosage Form (Powder, Suspension, Tablet, Eye drops, Intravenous preparation) Application (Urinary tract infections, Lower respiratory infections, Nosocomial pneumonia, Others), and Regional Analysis for 2026 – 2033
Drug-Resistant Tuberculosis Market by Drug Class (Amoxicillin/Clavulanate, Bedaquiline, Carbapenems with Clavulanic Acid, Clofazimine, Others), Disease Type (Active TB, Latent TB), Treatment Type, Distribution Channel, and Regional Analysis for 2026 - 2033
About Persistence Market Research:
At Persistence Market Research, we are pioneers in Market Research and Consulting, bringing you the most dynamic insights into market trends, consumer behaviours, and competitive intelligence! For over a decade, we've been at the forefront of delivering game-changing analytics and research that drive businesses toward growth.
Our extensive market report database is a go-to resource for Fortune 500 companies, savvy business investors, media and entertainment channels, and academic institutions, empowering them to navigate the global and regional business landscape with confidence. With thousands of statistics and in-depth analyses covering over 20 diverse industries across 25 major countries, we provide the insights you need to succeed in today's competitive environment.
Contact
Ankush Nikam
Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ
+44 203-837-5656
United Kingdom
USA Phone - +1 646-878-6329
Email: [email protected]
Logo: https://mma.prnewswire.com/media/2876873/Persistence_Market_Research_Logo.jpg
SOURCE Persistence Market Research Pvt. Ltd.